UK markets closed
NIKKEI 225
26,804.60 -244.87 (-0.91%) HANG SENG
21,996.89 -422.08 (-1.88%) CRUDE OIL
109.49 -2.27 (-2.03%) GOLD FUTURES
1,819.90 -1.30 (-0.07%) DOW
31,029.31 +82.32 (+0.27%) BTC-GBP
16,625.31 -182.91 (-1.09%)
GlaxoSmithKline plc (GSK.L)
LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
At close: 06:02PM BST
| Previous close | 1,766.00 |
| Open | 1,757.80 |
| Bid | 1,789.80 x 0 |
| Ask | 1,789.80 x 0 |
| Day's range | 1,751.40 - 1,793.00 |
| 52-week range | 1,215.83 - 2,726.53 |
| Volume | |
| Avg. volume | 11,947,072 |
| Market cap | 91.157B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 1,775.25 |
| EPS (TTM) | 1.01 |
| Earnings date | 27 Jul 2022 |
| Forward dividend & yield | 0.75 (4.25%) |
| Ex-dividend date | 19 May 2022 |
| 1y target est | 1,805.24 |
- Business Wire
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
PHILADELPHIA, June 29, 2022--GSK selects Target the Future grant recipient in innovation challenge supporting multiple myeloma community
- Zacks
GlaxoSmithKline (GSK) Stock Moves -0.8%: What You Should Know
GlaxoSmithKline (GSK) closed the most recent trading day at $43.35, moving -0.8% from the previous trading session.
- Zacks
Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.
© 2022 Yahoo. All rights reserved.
